TORONTO -- A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough therapy designation to elranatamab for treatment of relapsed or refractory multiple ...

Credit: Getty Images. Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

Data presented at the 2022 American Society of Hematology (ASH) annual meeting showed that elranatamab induces responses in relapsed or refractory multiple myeloma, and has a manageable safety profile ...

(RTTNews) - Pfizer Inc. (PFE) said that its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of ...

Pfizer has announced updated results from the MagnetisMM clinical development programme evaluating its investigational cancer immunotherapy, elranatamab, in multiple myeloma. Multiple myeloma is a ...

Pfizer has shared 10.4 month follow-up data from its pivotal phase 2 MagnetisMM-3 clinical trial, with results suggesting that elranatamab is effective and offers a manageable safety profile in those ...